市場調查報告書
商品編碼
1554521
Componen(3D 生物列印機、支架、生物材料)、應用(研究、臨床)、最終用戶(醫院、研究組織和學術機構、生物製藥公司)和地區的日本 3D 生物列印市場報告 2024-2032Japan 3D Bioprinting Market Report by Componen (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2024-2032 |
日本3D生物列印市場規模預計在2024-2032年期間呈現16.73%的成長率(CAGR)。老年人口對器官移植的需求不斷增加,以及獲得醫療技術的便利性,主要推動了市場的成長。
3D (3D) 生物列印是一種積層製造技術,專為精確製造解剖組織而開發。此方法涵蓋各種沉積和組裝工藝,包括直接寫入和雷射寫入、微沖壓、光刻、立體光刻、電子印刷和噴墨沉積。除此之外,它還依靠基於細胞的生物墨水的逐層組裝來構建3D組織和器官結構,這些生物墨水是使用活細胞、生物材料和活性生物分子配製而成的。透過沉積多層生物材料,3D 生物列印可以創建複雜的身體結構,如骨骼、皮膚、軟骨、血管移植物、氣管夾板和心臟組織。因此,它在日本各地的醫院、研究機構、學術機構和生物製藥公司中得到了廣泛的應用。
在日本市場背景下,越來越重視減少動物試驗是對該行業產生積極影響的重要因素。此外,對3D生物列印的需求不斷成長,特別是在更容易患各種慢性疾病的老年族群中,正在培育良好的市場前景,從而成為另一個重要的成長誘導因素。除此之外,晶片器官系統的開發等技術進步也正在推動市場成長。此外,全球對再生醫學、癌症治療和幹細胞解決方案的需求不斷成長,也促進了市場的擴張。除此之外,日本的醫療保健產業擴大採用3D生物列印,與其他產業相比,其干擾程度相對較低,為市場成長提供了大力支持。此外,知名製造商非常重視旨在推出生物印刷紙巾的研發(R&D)活動,這對區域市場產生了正面影響。這項努力旨在降低與新創新相關的成本並簡化藥物發現流程,進一步推動日本國內的進步。所有上述因素預計將在預測期內促進市場成長。
IMARC Group提供了每個細分市場的主要趨勢分析,以及 2024-2032 年國家層級的預測。我們的報告根據組件、應用程式和最終用戶對市場進行了分類。
該報告根據組成部分提供了詳細的市場細分和分析。這包括 3D 生物列印機(注射器/擠出生物列印、噴墨生物列印、磁懸浮生物列印、雷射輔助生物列印等)、支架和生物材料(活細胞、水凝膠、細胞外基質等)。
報告還提供了基於應用程式的詳細市場細分和分析。這包括研究(藥物研究、再生醫學和 3D 細胞培養)和臨床(皮膚、骨骼和軟骨、血管等)。
該報告提供了基於最終用戶的詳細市場細分和分析。這包括醫院、研究機構和學術機構以及生物製藥公司。
該報告還對所有主要區域市場進行了全面分析,包括關東地區、關西/近畿地區、中部/中部地區、九州沖繩地區、東北地區、中國地區、北海道地區和四國地區。
市場研究報告也對競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外,也提供了所有主要公司的詳細資料。
此處未提供公司名稱,因為這是目錄範例。報告中提供了完整的清單。
Japan 3D bioprinting market size is projected to exhibit a growth rate (CAGR) of 16.73% during 2024-2032. The elevating need for organ transplantation among the geriatric population, along with the easy access to medical technologies, is primarily driving the market growth.
Three-dimensional (3D) bioprinting is an additive manufacturing technique developed for the precise fabrication of anatomical tissues. This method encompasses various deposition and assembly processes, including direct and laser writing, microstamping, photolithography, stereolithography, electro-printing, and inkjet deposition. In addition to this, it relies on the layer-by-layer assembly of cell-based bio-inks, which are formulated using living cells, biomaterials, and active biomolecules, to construct 3D tissue and organ structures. By depositing multiple layers of biomaterials, 3D bioprinting can create complex bodily structures such as bones, skin, cartilage, vascular grafts, tracheal splints, and heart tissues. Consequently, it finds extensive applications in hospitals, research institutions, academic establishments, and biopharmaceutical companies across Japan.
In the context of the Japan market, the increasing emphasis on reducing animal testing is a significant factor positively influencing the industry. Additionally, the rising demand for 3D bioprinting, particularly among the elderly population who are more susceptible to various chronic illnesses, is fostering a favorable market outlook, thereby acting as another significant growth-inducing factor. Besides this, technological advancements such as the development of organ-on-a-chip systems are also driving market growth. Furthermore, the surging global demand for regenerative medicines, cancer therapeutics, and stem cell solutions is contributing to the expansion of the market. Apart from this, the healthcare sector in Japan is increasingly adopting 3D bioprinting, and its relatively lower disruption level compared to other industries is providing substantial support to market growth. Moreover, prominent manufacturers are placing a strong focus on research and development (R&D) activities aimed at introducing bio printed tissues, which is positively influencing the regional market. This effort aims to reduce the cost associated with new innovations and streamline the drug discovery process, further propelling advancement within Japan. All these above mentioned factors are expected to catalyze the market growth over the forecasted period.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on component, application, and end user.
The report has provided a detailed breakup and analysis of the market based on the component. This includes 3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others).
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes research (drug research, regenerative medicine, and 3D cell culture) and clinical (skin, bone and cartilage, blood vessels, and others).
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research organization and academic institutes, and biopharmaceuticals companies.
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.